Full Text View
Tabular View
No Study Results Posted
Related Studies
Atorvastatin Therapy for the Prevention of Atrial Fibrillation (SToP-AF)
This study has been terminated.
( This study was terminated because it was unlikely to have sufficient power to show a difference with therapy on an interim analysis. )
Study NCT00252967   Information provided by Emory University

First Received on November 14, 2005.   Last Updated on October 27, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Atrial Fibrillation
Inflammation
More general conditions related to this trial
Arrhythmias, Cardiac
Cardiovascular Diseases
Heart Diseases
Pathologic Processes
Interventions listed in this trial
80 mg daily of atorvastatin
Additional drug interventions recognized in this trial
Atorvastatin
More general drug interventions related to this trial
Anticholesteremic Agents
Antimetabolites
Enzyme Inhibitors
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Hypolipidemic Agents
Lipid Regulating Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses
Sponsors listed in this trial
Emory University
Pfizer


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services